Citadel Advisors’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-30
| Closed | -$150 | – | 15797 |
|
|
2024
Q3 | $150 | Sell |
30
-340
| -92% | -$2.21K | ﹤0.01% | 14086 |
|
|
2024
Q2 | $2.44K | Buy |
+370
| New | +$2.52K | ﹤0.01% | 13685 |
|
|
2023
Q3 | – | Sell |
-1,196
| Closed | -$46K | – | 15642 |
|
|
2023
Q2 | $46K | Sell |
1,196
-819
| -41% | -$28.9K | ﹤0.01% | 11898 |
|
|
2023
Q1 | $55.8K | Buy |
2,015
+1,604
| +390% | +$54.4K | ﹤0.01% | 12016 |
|
|
2022
Q4 | $13.5K | Sell |
411
-41
| -9% | -$2.99K | ﹤0.01% | 13440 |
|
|
2022
Q3 | $55K | Sell |
452
-706
| -61% | -$127K | ﹤0.01% | 11564 |
|
|
2022
Q2 | $203K | Sell |
1,158
-724
| -38% | -$153K | ﹤0.01% | 10665 |
|
|
2022
Q1 | $546K | Buy |
1,882
+443
| +31% | +$168K | ﹤0.01% | 9178 |
|
|
2021
Q4 | $752K | Buy |
1,439
+649
| +82% | +$466K | ﹤0.01% | 8648 |
|
|
2021
Q3 | $300K | Buy |
790
+708
| +863% | +$304K | ﹤0.01% | 11063 |
|
|
2021
Q2 | $73K | Buy |
+82
| New | +$62.7K | ﹤0.01% | 13138 |
|
Citadel Advisors's BIOR Position: Q2 2023 in Review
Citadel Advisors sold out of Biora Therapeutics, Inc. Common Stock (BIOR) in Q2 2023, closing a stake of 139 shares — an estimated $4.9K sold.
Citadel Advisors first reported a position in BIOR in Q2 2020 and held it in 8 quarters. The position peaked at $900K in Q2 2020. 30 funds tracked by Wall St. Rank hold BIOR as of Q2 2023.
- Citadel Advisors reported no remaining Biora Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Citadel Advisors sold 139 Biora Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $4.9K.
- Citadel Advisors first reported a position in Biora Therapeutics, Inc. Common Stock in Q2 2020 and held it in 8 quarters.
- Citadel Advisors's Biora Therapeutics, Inc. Common Stock position peaked at $900K in Q2 2020.
- 30 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q2 2023.
Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.